Drug companies try all kinds of nonsense to keep selling their brand-name drugs, when the same drugs are also sold as over-the-counter store-name generics. Sanofi just started a sleazy marketing campaign trying to do just that. And it's not their first time either.
Can the FDA's tactics – to impact the current opioid problem – also predict its successor? The goal is to head off escalation before problems are crises, and the move is a departure from the status-quo, reactive nature of prior policies.